AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

799.528

+4.4020.55%

Number of Gainers:16

Number of Losers:5

Number of Flat:24

PE:- -

High:801.011

Open:795.126

Low:789.417

Close:795.126

Loading ...

Thursday’s HotCopper Trends: Sayona merger, Opthea slashes jobs | April 10, 2025

The Market Herald

The Fallen: Stocks hitting 52-week lows (and what investors should do)

BRIEF-Opthea Says Reducing Workforce By 65%

Opthea Cuts 65% Staff, Terminates Drug Trials

MT Newswires Live

Opthea, with shares still suspended, cuts workforce by 65% after drug trials cancelled

The Market Herald

Cann Group Ltd-Proposed Issue of Securities - Can

THOMSON REUTERS

Opthea Ltd - Reducing Its Workforce by Approximately 65%

THOMSON REUTERS

Opthea - Material Uncertainty on Co's Ability to Continue as Going Concern

THOMSON REUTERS

Opthea Ltd - One-off Costs Associated With Reduction in Force Will Be Approximately US$4.5M

THOMSON REUTERS

Orthocell - Submits Regulatory Application to Commence Sales of Remplir in Hong Kong

THOMSON REUTERS

What would Warren Buffett do with ASX shares in this market selloff? Probably this…

Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare

AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025

3 ASX Stocks Estimated To Be Up To 49.8% Below Intrinsic Value

Simply Wall St.

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

UXLINK's Q1 2025 Growth and Profit Soar, Paving the Way for Industry Growth

Respiri Confirms No Material Impact on Business Operations from US Tariffs on Chinese-Manufactured Medical Devices

MT Newswires Live

Why Mineral Resources, Polynovo, Regal Partners, and Santos shares are falling today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":799.52814,"timestamp":1745474399881,"preClose":795.126,"halted":0,"volume":54911678,"delay":0,"changeRate":0.005536,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":4.402161,"latestTime":"04-24 16:00:00 AEST","open":795.126,"high":801.01086,"low":789.4166,"amount":126091203,"amplitude":0.014582,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745798400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745452800000,1745474400000]],"turnoverRate":0.001533,"increases":18,"decrements":5,"flats":20,"marketCap":126444366382.875,"floatMarketCap":123750989381},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":801.01086,"amplitude":0.014582,"preClose":795.126,"low":789.4166,"latestPrice":799.52814,"volume":54911678,"delay":0,"open":795.126,"prevYearClose":936.801,"prevWeekClose":793.051,"prevMonthClose":815.605,"prevQuarterClose":815.605,"fiveDayClose":805.476,"twentyDayClose":842.87,"sixtyDayClose":909.271,"secType":"PLATE","market":"AU","turnoverRate":0.001533,"marketCap":126444366382.875,"floatMarketCap":123750989381,"timestamp":1745474399881,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":16,"down":5,"flat":24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526776643","title":"Thursday’s HotCopper Trends: Sayona merger, Opthea slashes jobs | April 10, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526776643","media":"The Market Herald","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526776643?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:04","pubTimestamp":1744254240,"startTime":"0","endTime":"0","summary":"The ASX has been up, charging 4.7% higher at around 7,720 points today.Sayona Mining  has been among the most watched on HotCopper forums on news it has merged with NASDAQ-listed Piedmont Lithium. The name of the company will be changed to Elevra Lithium once the deal closes.Sayona Mining has been 1.6 cents in early afternoon trades.BOSS Energy  has also been trending on the forums after presenting at the Resources Rising Stars conference today. The company shared actual production and sales results for Q3 FY25.Finally, Opthea  shared a corporate update after the termination of its COAST Phase 3 clinical trials. In light of the negative trial results, the Board has decided to reduce costs and has slashed 65% of the workforce.Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.The material provided in this article is for information only and should not be treated as investment advice. Vi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/thursdays-hotcopper-trends-sayona-merger-opthea-slashes-jobs-april-10-2025-2025-04-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BOE.AU","SYA.AU","BK4139","BK7508","BK7083","BK7067","OPT","BK7095","BK7504","OPT.AU"],"gpt_icon":0},{"id":"2526364374","title":"The Fallen: Stocks hitting 52-week lows (and what investors should do)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526364374","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526364374?lang=en_us&edition=fundamental","pubTime":"2025-04-10 10:48","pubTimestamp":1744253281,"startTime":"0","endTime":"0","summary":"Earlier this week, I covered The Outlaws – stocks hitting 52-week highs despite the market sinking.The Outlaw Stocks: The ASX names defying the sell-off and hitting 52-week highs. Unlike in 2022, when almost every asset class fell in lockstep, this year we’ve seen defensives and fixed income ETFs do what they’re meant to do: offer ballast in a storm.Now, let's flip the script and look at the stocks and ETFs which hit 52-week lows before today's bigger-than-Ben-Hur rally. We'll call them:The Fallen.To be sure, these aren’t necessarily all bad businesses. As fund managers like Emanuel Datt, Adam Dawes, and Nick Peros have pointed out, a stock hitting a 52-week low isn’t always a red flag.It's a potential opportunity to pick up quality at a discount.Due to the sheer number of names hitting 52-week low, we’ve  focused this wire on two key ASX sectors – resources and financials – with expert insights to help investors make sense of the wreckage.You can download the full list below or use th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-fallen-stocks-hitting-52-week-lows-and-what-investors-should-do","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU0158827948.USD","LU0795875169.SGD","LU1732800096.USD","BK4552","XRO.AU","RMD","LU0225283273.USD","BK4516","NDQ.AU","REA.AU","NXL","BK7508","LU1868837136.USD","GQG.AU","LU0795875086.SGD","LU2008162690.USD","RMD.AU","LU0912757837.SGD","LU2471134879.HKD","BHP.AU","LU2023251221.USD","MFG.AU","LU2028103732.USD","PNI.AU","LU2471134523.USD","LU1162221912.USD","BK4585","LU0170899867.USD","TNE.AU","CSL.AU","LU2237443549.SGD","IE00B19Z3B42.SGD","MQG.AU","BK7507","LU0314104364.USD","LU0742534661.SGD","LU2089283258.USD","LU2237438978.USD","LU1548497426.USD","BK4127","LU0251131958.USD","MIN.AU","RIO.AU","BK4550","LU2237443978.SGD","LU2089284900.SGD","NXL.AU","BK7016","BK7002","LU2471134796.USD"],"gpt_icon":0},{"id":"2526322798","title":"BRIEF-Opthea Says Reducing Workforce By 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526322798","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526322798?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:31","pubTimestamp":1744248712,"startTime":"0","endTime":"0","summary":"BRIEF-Opthea Says Reducing Workforce By 65%April 10  - Opthea Ltd OPT.AX:REDUCING ITS WORKFORCE BY APPROXIMATELY 65%ONE-OFF COSTS ASSOCIATED WITH REDUCTION IN FORCE WILL BE APPROXIMATELY US$4.5MMATERIAL UNCERTAINTY ON CO'S ABILITY TO CONTINUE AS GOING CONCERNFurther company coverage: OPT.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN1YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2526324926","title":"Opthea Cuts 65% Staff, Terminates Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2526324926","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526324926?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:16","pubTimestamp":1744247818,"startTime":"0","endTime":"0","summary":"Opthea  has terminated phase three clinical trials for two of its drug candidates following negative results, according to a Thursday Australian bourse filing.The company will be reducing its workforce by about 65% to cut costs while retaining a limited number of employees to ensure compliant termination of clinical trial activities and oversee administrative operations, the filing added.The company expects the workforce reduction to take effect from May 1 with one-off costs of about $4.5 million, resulting reduction in monthly employee costs of $1 million.The company sees unaudited cash and cash equivalents of $100 million at the end of March.The company said its ability to continue as a going concern remains materially uncertain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","OPT.AU","BK4139","OPT"],"gpt_icon":0},{"id":"2526129322","title":"Opthea, with shares still suspended, cuts workforce by 65% after drug trials cancelled","url":"https://stock-news.laohu8.com/highlight/detail?id=2526129322","media":"The Market Herald","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526129322?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:07","pubTimestamp":1744247220,"startTime":"0","endTime":"0","summary":"Troubled biotech stock Opthea , still in the process of crisis talks with investors, has flagged a workforce reduction of -65%.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.This comes not long after Opthea’s flagship Phase 3 trial treating age-related vision loss came up empty-handed because its drug of interest simply wasn’t proven to be effective.Those results prompted Opthea to abandon not one, but two trials; and now, what was a former favourite among HotCopper‘s myriad biotech watchers, is quickly becoming a letdown.Probably nobody is more aware of this than Opthea.“As previously disclosed, the company remains in active negotiations with its [keystone] investors… to explore possible options to deliver the best outcome for the company and its shareholders,” the company wrote.The material provided in this article is for information only and should not be treated as investment a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/opthea-with-shares-still-suspended-cuts-workforce-by-65-after-drug-trials-cancelled-2025-04-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4139","OPT","BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2526328793","title":"Cann Group Ltd-Proposed Issue of Securities - Can","url":"https://stock-news.laohu8.com/highlight/detail?id=2526328793","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526328793?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:54","pubTimestamp":1744242845,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUEBWDH5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","CAN.AU","BK7502"],"gpt_icon":0},{"id":"2526401613","title":"Opthea Ltd - Reducing Its Workforce by Approximately 65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526401613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526401613?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:21","pubTimestamp":1744240903,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2526340191","title":"Opthea - Material Uncertainty on Co's Ability to Continue as Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2526340191","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526340191?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:21","pubTimestamp":1744240903,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OPT.AU","BK7067"],"gpt_icon":0},{"id":"2526340164","title":"Opthea Ltd -  One-off Costs Associated With Reduction in Force Will Be Approximately US$4.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2526340164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526340164?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:21","pubTimestamp":1744240903,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN1YR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OPT.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2526347210","title":"Orthocell -  Submits Regulatory Application to Commence Sales of Remplir in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2526347210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526347210?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:00","pubTimestamp":1744239655,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QN23A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OCC.AU","BK7067"],"gpt_icon":0},{"id":"2526342137","title":"What would Warren Buffett do with ASX shares in this market selloff? Probably this…","url":"https://stock-news.laohu8.com/highlight/detail?id=2526342137","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526342137?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:12","pubTimestamp":1744233165,"startTime":"0","endTime":"0","summary":"When markets fall and fear takes over, investors tend to ask the same question: What would Warren Buffett do?While we can't know for sure what the Oracle of Omaha would do with ASX shares during this market selloff, we can look to his decades of wisdom and actions for clues. And if history is any guide, there's a good chance he wouldn't be panicking — he would be preparing. What would Warren Buffett do with ASX shares?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/10/what-would-warren-buffett-do-with-asx-shares-in-this-market-selloff-probably-this/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["FDN","BK4534","IE00BK4W5M84.HKD","BK7501","LU0787776722.HKD","LU1914381329.SGD","BK7153","IE00B1XK9C88.USD","LU0234572021.USD","IE00B3S45H60.SGD","LU1074936037.SGD","WES.AU","BK4585","BK4533","IE00BJLML261.HKD","LU0648001328.SGD","LU0971096721.USD","LU0417517546.SGD","BK7511","CSL.AU","LU0048573561.USD","LU0256863811.USD","BK7508","LU0683600562.USD","LU0742534661.SGD","LU0251131958.USD","LU0980610538.SGD","LU0154236417.USD","LU1363072403.SGD","LU0149725797.USD","NDQ.AU","IE0034235303.USD","LU1280957306.USD","LU1201861249.SGD","LU1571399168.USD","LU0234570918.USD","MOAT.AU","IE00BWXC8680.SGD","LU0053666078.USD","BK4176","BK4588","MQG.AU","VAS.AU","LU1366333091.USD","IE00BK4W5L77.USD","IE00B775SV38.USD","LU0157215616.USD","BRK.B","LU0170899867.USD","BK4550"],"gpt_icon":1},{"id":"2526990342","title":"Trump 2.0: Macquarie's take on the winners and losers in Australian healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2526990342","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526990342?lang=en_us&edition=fundamental","pubTime":"2025-04-10 05:12","pubTimestamp":1744233120,"startTime":"0","endTime":"0","summary":"] A key challenge for both RMD and FPH will be negotiations with US payors to increase pricing or widening co-payments. We note upside risk for both names if respiratory devices/apparatus are exempt from tariffs under the Nairobi Protocol implemented through the Harmonised Tariff Schedule.  That said, ResMed isn't completely immune. With part of its manufacturing based in Australia and Singapore, both now facing 10% tariffs, and rising input costs from tariffed raw materials, its earnings forecasts have been trimmed by 2% for FY 2026 and FY 2027. What about CSL and Cochlear?Biotech giant CSL Ltd  escaped the current round of tariffs, thanks to exemptions for pharmaceutical products. However, Macquarie flagged it as a name to watch. It said:  CSL is left unscathed by reciprocal tariffs as pharmaceuticals are exempted. However, potential sector tariffs remain a key risk for CSL in the near term.  As for Cochlear Ltd , it also sidestepped the tariff net, as hearing devices continue to enj","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/10/trump-2-0-macquaries-take-on-the-winners-and-losers-in-australian-healthcare/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7501","BK7511","XJO.AU","BK7046","CSL.AU","BK7126","BK7508","MQG.AU","FPH.AU","XKO.AU","BK7067","XAO.AU","BK7007","COH.AU","ANN.AU","RMD.AU"],"gpt_icon":0},{"id":"2526433613","title":"AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526433613","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526433613?lang=en_us&edition=fundamental","pubTime":"2025-04-10 04:05","pubTimestamp":1744229100,"startTime":"0","endTime":"0","summary":"Sixteen abstracts to present real-world findings and clinical innovations across AVITA Medical’s expanded portfolio, including RECELL, Cohealyx, and PermeaDerm. VALENCIA, Calif., April 09, 2025  -- AVITA Medical, Inc. , a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association  2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona. The presentations will feature real-world and clinical data on AVITA Medical’s wound care portfolio, including RECELL, Cohealyx, and PermeaDerm, showcasing the company’s expanded evidence base and commitment to improving outcomes in burn and wound management. Visit AVITA Medical at booth #513 to learn more.Each year, more than 450,000 Americans require medical treatment for burn injuries, often facing prolonged hospitalization, multiple procedures, and complex wound management. AVITA Medical’s technologies are designed to address ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avita-medical-present-breakthrough-clinical-200500697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","BK7067","BK7139","AVH.AU","BK7508","BK7123","ABA.AU","RCEL"],"gpt_icon":0},{"id":"2526334884","title":"3 ASX Stocks Estimated To Be Up To 49.8% Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2526334884","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526334884?lang=en_us&edition=fundamental","pubTime":"2025-04-10 03:34","pubTimestamp":1744227269,"startTime":"0","endTime":"0","summary":"The Australian market has recently experienced significant volatility, with tariff-driven panic selling affecting most sectors and energy stocks being particularly hard hit due to a drop in Brent Crude prices. Amidst these challenging conditions, identifying undervalued stocks can present opportunities for investors looking to capitalize on price discrepancies relative to intrinsic value.Top 10 Undervalued Stocks Based On Cash Flows In Australia. Deep Yellow is trading at A$0.79, significantly below its estimated fair value of A$1.56, suggesting it may be undervalued based on cash flows. The company reported a substantial revenue increase to A$6.29 million for the half-year ended December 2024, though it remains unprofitable with a net loss of A$2.47 million. Expected revenue growth of 137.6% annually outpaces the market average, supporting its potential as an undervalued opportunity despite current losses.Lynas Rare Earths is trading at A$7.69, slightly below its estimated fair value ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-stocks-estimated-49-193429442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["DYL.AU","MVP.AU","XJO.AU","DSK.AU","BK7083","BK7107","BK7503","PNR.AU","BK7124","BK7128","BK7117","BK7104","JHX.AU","SHV.AU","BK7088","BK7044","LBL.AU","LYC.AU","XAO.AU","XKO.AU","BK7096","IDX.AU","BK7505","BK7507","BK7508","POL.AU","NCK.AU","BK7095","BK7043","MP1.AU"],"gpt_icon":0},{"id":"2526381051","title":"CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526381051","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526381051?lang=en_us&edition=fundamental","pubTime":"2025-04-09 15:01","pubTimestamp":1744182060,"startTime":"0","endTime":"0","summary":"0701 GMT - Australia-based biotech company CSL, which collects plasma in the U.S. and manufactures many plasma-based products at plants in Europe, would likely need to raise prices by between 4% to 5.1% to offset Trump's planned tariffs on pharmaceuticals, say Jefferies analysts. While it isn't clear exactly how the Trump pharmaceutical tariffs will work, the good news for CSL is that over time it may be able to move plasma product manufacturing from high tariff locations in Europe to lower tariff areas like Australia, say David Stanton and Vanessa Thomson. This will put it in a slightly better position than its major European competitors. But in general, \"plasma companies may see difficulties transferring complex, expensive operations at plants that can take years to build,\" they add. CSL shares ended 5% lower. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004303.SGD","CSL.AU","BK4086","CSL","SGXZ23171101.USD","BK7501","LU1169589451.USD","LU1169590202.USD","LU0728928796.USD","BK7067","BK7508","BK7511"],"gpt_icon":0},{"id":"2526220382","title":"UXLINK's Q1 2025 Growth and Profit Soar, Paving the Way for Industry Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2526220382","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526220382?lang=en_us&edition=fundamental","pubTime":"2025-04-09 14:38","pubTimestamp":1744180680,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 9th: In the challenging market environment of the first quarter of 2025, UXLINK not only achieved strong growth but also recorded solid profits.The UXLINK ecosystem has always been centered on \"growth,\" committed to providing users with a seamless experience, and enabling healthy growth for projects and builders through top-notch infrastructure, tools, and traffic support. With successful Product-Market-Fit  validation, as long as the industry maintains its upward momentum, the demand for growth will never diminish. The UXLINK ecosystem's Minimum-Viable-Product  has also been fully validated, achieving a net profit of over tens of millions of dollars, entering a positive cycle.The head of the UXLINK ecosystem stated: We expect the full-year net profit for 2025 to reach $20-30 million. Looking ahead, with the introduction of the PAYFI system, next-generation AI tools, and more innovative projects, UXLINK's profits will experience explosive growth!We will continue ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/288963","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["PMF","BK7096","MVP.AU","MVP","BK7508"],"gpt_icon":0},{"id":"2526388885","title":"Respiri Confirms No Material Impact on Business Operations from US Tariffs on Chinese-Manufactured Medical Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=2526388885","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526388885?lang=en_us&edition=fundamental","pubTime":"2025-04-09 13:29","pubTimestamp":1744176558,"startTime":"0","endTime":"0","summary":"Respiri  confirmed that the recent U.S. tariffs on Chinese-manufactured medical devices will have no material impact on its business operations, according to a Wednesday Australian bourse filing.It said that it has already over two years' worth of inventory for its wheezo device in the US.While the tariffs may increase supply costs by around $30 per device for other medical devices, the company can absorb the increase internally, with no change to client pricing or margin exposure, or disruption to existing and new Respiri clients, the filing said.It noted that US Health Secretary Robert F. Kennedy Jr. advocated for scaling artificial intelligence, telehealth, and virtual care technologies through the healthcare system, which it said supports its connected care business model.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","RSH.AU","BK7503","BK7007"],"gpt_icon":0},{"id":"2526238608","title":"Why Mineral Resources, Polynovo, Regal Partners, and Santos shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2526238608","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526238608?lang=en_us&edition=fundamental","pubTime":"2025-04-09 12:48","pubTimestamp":1744174106,"startTime":"0","endTime":"0","summary":"In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is out of form and dropping into the red. At the time of writing, the benchmark index is down 2% to 7,353.5 points. Four ASX shares that are fallin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/04/09/why-mineral-resources-polynovo-regal-partners-and-santos-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7095","BK7508","STO.AU","BK7507","BK7062","BK7126","PNV.AU","RPL.AU","XJO.AU","BK7504","MIN.AU","BK7142"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":118,"code":"91000000","status":"200"}]}}